Participants
3 patients 0-17 years with Cystic Fibrosis
Interventions
VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kalydeco 150 mg film-coated tablets, VX-770 75mg, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 75 mg film-coated tablets, Kalydeco 75 mg granules in sachet
Outcome measures
Safety and tolerability of ELX/TEZ/IVA based on adverse events (AEs), clinical laboratory values, standard 12-lead ECGs, vital signs, and pulse oximetry